Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type Clinical Trial
Official title:
PD-1 Blockade With Pembrolizumab in Relapsed or Refractory Natural Killer/T Cell Lymphoma
The purpose of this study is to evaluate the efficacy and safety of PD-1 blockade pembrolizumab for patients with relapsed or refractory Natural Killer(NK)/T Cell Lymphoma.
Patients with relapsed or refractory NK/T cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional chemotherapy. The investigators have been proceeding this trial to evaluate the efficacy and safety of the immune checkpoint inhibitor PD-1 blockade, pembrolizumab in the patients with relapsed or refractory NK/T cell lymphoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05058755 -
Tislelizumab Combined Treatment in Refractory Extranodal NK/T-cell Lymphoma
|
N/A | |
| Recruiting |
NCT06314334 -
Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03618238 -
Anlotinib for Advanced and Refractory Natural Killer /T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04004572 -
Sintilimab, Pegaspargase and Anlotinib for Stage IV Natural Killer /T-cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03623087 -
SIMPLE Chemotherapy for NK Lymphoma/Leukaemia
|
Phase 3 | |
| Recruiting |
NCT03630731 -
Maintenance Treatment of Chidamide in Stage IV or Relapsed/Refractory Extranodal NK/T-cell Lymphoma
|
Phase 2 | |
| Completed |
NCT03936452 -
Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04366128 -
Camrelizumab, Pegaspargase and Apatinib With Radiation Therapy for Stage IE/IIE ENKTL
|
N/A |